Performance Evaluation of the VIDAS® Measles IgG Assay and Its Diagnostic Value for Measuring IgG Antibody Avidity in Measles Virus Infection

The objective of this study is primarily to compare the performance of the VIDAS (R) Measles immunoglobulin (Ig) G assay to that of two other serological assays using an immunoassay technique, Enzygnost (R) Anti-measles Virus/IgG (Siemens) and Measles IgG CAPTURE EIA (R) (Microimmune). The sensitivity and the agreement of the VIDAS (R) Measles IgG assay compared to the Enzygnost (R) Anti-measles Virus/IgG assay and the Measles IgG CAPTURE EIA (R) assay are 100%, 97.2% and 99.0%, 98.4%, respectively. The very low number of negative sera for IgG antibodies does not allow calculation of specificity. As a secondary objective, we have evaluated the ability of the VIDAS (R) Measles IgG assay to measure anti-measles virus IgG antibody avidity with the help of the VIDAS (R) CMV IgG Avidity reagent, using 76 sera from subjects with measles and 238 other sera. Different groups of populations were analyzed. In the primary infection measles group, the mean IgG avidity index was 0.16 (range of 0.07 to 0.93) compared to 0.79 (range of 0.25 to 1) in the serum group positive for IgG antibodies and negative for IgM. These data allow to define a weak anti-measles virus IgG antibody avidity as an avidity index (AI) < 0.3 and a strong avidity as an AI > 0.6. The VIDAS (R) Measles IgG assay has a performance equivalent to that of other available products. Its use, individual and quick, is well adapted to testing for anti-measles immunity in exposed subjects.